HopeStage
Back to all studies
CompletedNCT00512070

Olanzapine, sleep, and metabolic changes in schizophrenia

About this titleRead the official source — NCT00512070
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
TacomaSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 2007
Recruitment status
Completed
Enrollment listed in the registry
40
Sponsor
Seattle Institute for Biomedical and Clinical Research
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00512070
Official title
Show the full official title

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tacoma

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Seattle Institute for Biomedical and Clinical Research, a research institute.

Did this study involve medication?

Yes. The study involved medication, including olanzapine and melatonin.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies